Characterization of human erythrocyte membrane-bound acetylcholinesterase inhibition by cisplatin at reversible phase

Anticancer Research

Volumn 16, Issue 6 B, 1996, Pages 3725-3730

  Kamal, Mohammad Amjad ^a  

^a KING SAUD UNIVERSITY   (Saudi Arabia)

Author keywords

Acetylcholinesterase; Cisplatin; Erythrocyte membrane bound; Inhibition pharmacology; Kinetics; Reversible

Indexed keywords

ACETYLCHOLINESTERASE; ACETYLTHIOCHOLINE; CISPLATIN; MEMBRANE ENZYME;

ARTICLE; CHOLINESTERASE INHIBITION; CONTROLLED STUDY; DRUG HYDROLYSIS; ENZYME KINETICS; ERYTHROCYTE MEMBRANE; HUMAN; HUMAN CELL; MATHEMATICAL ANALYSIS; MICHAELIS CONSTANT; PRIORITY JOURNAL;

ACETYLCHOLINESTERASE; ANTINEOPLASTIC AGENTS; CHOLINESTERASE INHIBITORS; CISPLATIN; ERYTHROCYTE MEMBRANE; HUMANS; MALE; NEOPLASM PROTEINS; PHARMACOKINETICS;

EID: 0030485545     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Quinn DM: Acetylcholinesterase: enzyme structure, reaction dynamics, and virtual transition states. Chem Rev 87: 955-979, 1987.
2. Spandidos DA: A unified theory for the development of cancer. Bioscience Reports 6: 691-708, 1986.
3. Biswal N, Patel AG and Max SR: Regulation of viral and cellular genes in a human neuro blastoma cell line latently infected with herpes simplex virus type 2. Brain Res 427: 95-106, 1988.
4. Topilko A and Caillou B: Acetylcholinesterase and butyrylcholinesterase activities in human thyroid cancer cells. Cancer 61: 491-449, 1988.
5. Gurkalo VK and Volfson NI: Nicotine influence upon the development of experimental stomach tumors. Arch Geschwulstforsch 52(4): 259-265, 1982.
6. Loiselet J, Sabbagh W and Srouji G: Serum cholinesterase and erythrocyte acetylcholinesterase in 89 cases of cancer. Ann Biol Clin Paris 26: 659-664, 1968.
7. Piura B, Glezerman M and Cohen Y: Experience in the treatment of epithelial ovarian carcinoma with cisplatinum-containing combination chemotherapy and dose intensity calculation. Eur J Gynaecol Oncol 11: 389-393, 1990.
8. Einhorn LH: Combination chemotherapy with cis-dichlorodiammineplatinum (II) in disseminated testcular cancer. Cancer Treat Rep 63: 1659-1662, 1979.
9. Rozencgeig M, Von Hoff DD, Slavik M and Muggia FM: Cisdiamminedichloroplatinum (II): A new anticancer drug. Ann Intern Med 86: 803-812, 1977.
10. The Department of Veterans Affairs Laryngeal Cancer Study Group: Induction chemotherapy plus radiation in patients with advanced laryngeal cancer. N Engl J Med 324: 1685-1690, 1991.
11. Von Hoff DD, Schilsky R, Reichert CM, Reddick RL, Rozencweig M, Young RC and Muggia FM: Toxic effects of cis-dichlorodiammineplatinum (II) in man. Cancer Treat Rep 63: 1527-1531, 1979.
12. Calabresi P and Chabner BA: In: The Pharmacological Basis of Therapeutics (Gilman AG, Rall TW, Nies AS and Taylor P, eds). New York, Academic Press Inc, 1990, p 1202.
13. Berenstein A, Wise A, Carr RE and Ransohoff J: Visual system toxicity following intra arterial chemotherapy. Neurology 38: 284-289, 1988.
14. Sleijfer S, Graaf WTAVD, Willemse PHB, Vries EGED, Koops HS and Mulder NH: Highdose methotrexate, vincristine and cisplatin as salvage treatment for relapsed nonseminomatous germ-cell cancer. Anticancer Res 15: 1039-1042, 1995.
15. Eastman A: Interstrand cross-links and sequence specificity in the reaction of cis-dichlorl(ethylenediamine) platinum (II) with DNA. Biochemistry 24: 5027-5032, 1985.
16. Reed E, Yopsa SH, Zwelling, Ozols RF and Poirier MC: Quantitation of cis-diamminedi chloroplatinum II (cisplatin) DNA-intrastran adducts in testicular and ovarian cancer patients receiving cisplatin chemotherapy. J Clin Invest 77: 545-550, 1986.
17. Pinto AL and Lippard SJ: Sequence-dependent termination of in vitro DNA synthesis by cis- and trans- diamminedichloroplatinum (II). Proc Natl Acad Sci USA 82: 4616-4619, 1985.
18. Ciccarelli RB, Solomon MJ Varhavsky A and Lippard SJ: in vivo effect of cis- and trans- diamminedichloroplatinum (II) on SV40 chromosomes: differential repair, DNA-protein crosslinking, and inhibition of replication. Biochemistry 24: 7533-7540, 1985.
19. Rothstein A: In: Current Topics in Membranes and Transport (Bronner F and Kleinzeller A, eds). New York, Academic Press Inc, 1970, p 135.
20. Lablance GA and Waxman DJ: Interaction of anticancer drugs with hepatic monooxgenase. Drug Meta Rev 20: 395-439, 1989.
21. Sadzuka Y, Shoji T and Takino Y: Effect of cisplatin on the activites of enzymes which protect against lipid peroxidation. Biochemical Pharmacol 43: 1872-1875, 1992.
22. Al-Jafari AA, Duhaiman AS and Kamal MA: Inhibition of human acetylcholinesterase by cyclophosphamide. Toxicology 96: 1-6, 1995.
23. Qayyum MA, Fatani JA and El-Badawi MG: Partial degeneration of autonomic nerves of the heart of methotrexate-treated guinea pigs. Acta Anata 131: 52-55, 1988.
24. Al-Jafari AA, Kamal MA and Duhaiman AS: The mode of inhibition of human erythrocyte membrane-bound acetylcholinesterase by cisplatin in vitro. J Enzy Inhibit 8: 281-289, 1995.
25. 50 with time for the inhibition of human erythrocyte acetylcholinesterase by cisplatin. Cell Pharmacol 3: 45-48, 1996.
26. Kamal MA and Al-Jafari AA: The preparation and kinetic analysis of multiple forms of human erythrocyte acetylcholinesterase. Prep Biochem Biotech 26(2): in press, 1996.
27. Ellman GL, Courtney KD, Andres VJr and Featherstone RM: A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol 7: 88-95, 1961.
28. Al-Jafari AA and Kamal MA: Optimization and kinetic studies of human erythrocyte membrane-bound acetylcholinesterase. Biochem Mol Biol Int 38(3): 577-586, 1996.
29. Segel IH: Enzyme kinetics: Behaviour and analysis of rapid equilibrium and steadystate enzyme systems. New York: John Wiley and Sons, 1975, pp 136-143.
30. Lowry OH, Rosebrough NJ, Farr AI, and Ranadall RJ: Protein measurement with the Folin Phenol reagent. J Biol Chem 193: 265-275, 1951.
31. Al-Jafari AA and Kamal MA: The preparation and kinetic properties of multiple forms of chicken brain acetylcholinesterase. Cell Biochem Funct 12: 29-35, 1994.
32. Leatherbarrow RJ: GraFit. Version 3.0: Erithacus Software Ltd. Staines, UK.
33. Dixon M: The determination of enzyme inhibitor constant. Biochem J 55: 170-171, 1953.
34. Grzelinska E, Bartosz G and Bartkowiak A: Aging of the bovine erythrocyte acetylcholineste rase. Enzyme 30: 95-98, 1983.
35. Segel IH: Enzyme kinetics: Behaviour and analysis of rapid equilibrium and steadystate enzyme systems. New York: John Wiley and Sons, 1975, pp 188-189.
36. Cohen SG, Chishti SB, Bell DA, Howard SI, Salih E and Cohen JB: General occurence of binding to acetylcholinesterase-substrate complex in noncompetitive inhibition and in inhibition by substrate. Biochem Biophys Acta 1076: 112-122, 1991.
37. Taylor JL, Mayer RT and Himel CM: Conformers of acetylcholinesterase: a mechanism of allosteric control. Mol Pharmacol 45: 74-83, 1994.
38. Patterson TA, Terry AV and Kosh JW: Prevention of physostigmine-, DFP-, and diazinon induced acute toxicity by monoethylcholine and N-aminodeanol. Br J Pharmacol 97: 451-460, 1989.
39. Okonek S and Kilbinger H: Determination of acetylcholine, nitrostigmine and acetylcholinesterase activity in four patients with severe nitrostigmine (E 605 forte) intoxication. Arch Toxicol 32: 97-108, 1974.
40. Hodge AS, Humphrey DR and Rosenberry TL: Ambenonium is a rapidly reversible noncovalent inhibitor of acetylcholinesterase with one of the highest known affinities. Mol Pharmacol 41: 937-942, 1992.